RXFP2 and osteoporosis: This apparently independent effect of INSL3 on bone parameters is in agreement with other studies showing that mutations in either the INSL3 gene or that of its receptor, RXFP2, in mice or in humans is accompanied by significant osteopenia or osteoporosis (24), probably due to direct positive effects of the hormone on bone cell metabolism (25).